A neonatal mouse model of intestinal perforation: Investigating the harmful synergism between glucocorticoids and indomethacin

Journal of Pediatric Gastroenterology and Nutrition

Volumn 45, Issue 5, 2007, Pages 509-519

  Gordon, Phillip V ^a   Herman, Andrew C ^b   Marcinkiewicz, Marek ^a   Gaston, Benjamin M ^a   Laubach, Victor E ^c   Aschner, Judy L ^d  

^a UNIVERSITY OF VIRGINIA CHILDREN S HOSPITAL   (United States)

^b LEVINE CANCER INSTITUTE   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dexamethasone; Indomethacin; Neonatology; Nitric oxide synthetase; Spontaneous intestinal perforation; Steroid

Indexed keywords

DEXAMETHASONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOCORTICOID; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ILEUM; INTESTINE PERFORATION; KNOCKOUT MOUSE; MOUSE; NEWBORN; NONHUMAN; PERISTALSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYLORUS STENOSIS; RISK FACTOR; WILD TYPE;

ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENETIC PREDISPOSITION TO DISEASE; GLUCOCORTICOIDS; ILEUM; INDOMETHACIN; INTESTINAL PERFORATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; NITRIC OXIDE SYNTHASE; PERISTALSIS; PYLORIC STENOSIS; RISK FACTORS;

MUS;

EID: 37349104923     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181558591     Document Type: Article

References (43)

1. Attridge JT, Clark R, Walker MW, et al. New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure. J Perinatol 2006;26:93-9.
2. Attridge JT, Clark R, Walker MW, et al. New insights into spontaneous intestinal perforation using a national data set: (2) two populations of patients with perforations. J Perinatol 2006;26:185-8.
3. Gordon P, Rutledge J, Sawin R, et al. Early postnatal dexamethasone increases the risk of focal small bowel perforation in extremely low birth weight infants. J Perinatol 1999;19:573-7.
4. Tatekawa Y, Muraji T, Imai Y, et al. The mechanism of focal intestinal perforations in neonates with low birth weight. Pediatr Surg Int 1999;15:549-52.
5. Miserez M, Barten S, Geboes K, et al. Surgical therapy and histological abnormalities in functional isolated small bowel obstruction and idiopathic gastrointestinal perforation in the very low birth weight infant. World J Surg 2003;27:350-5.
6. Meyer CL, Payne NR, Roback SA. Spontaneous, isolated intestinal perforations in neonates with birth weight less than 1,000 g not associated with necrotizing enterocolitis. J Pediatr Surg 1991;26:714-7.
7. Blakely ML, Tyson JE, Lally KP, et al. Laparotomy versus peritoneal drainage for necrotizing enterocolitis or isolated intestinal perforation in extremely low birth weight infants: outcomes through 18 months adjusted age. Pediatrics 2006;117:E680-7.
8. Attridge JT, Herman AC, Gurka MJ, et al. Discharge outcomes of extremely low birth weight infants with spontaneous intestinal perforations. J Perinatol 2006;26:49-54.
9. Gordon PV, Young ML, Marshall DD. Focal small bowel perforation: an adverse effect of early postnatal dexamethasone therapy in extremely low birth weight infants. J Perinatol 2001;21:156-60.
10. Garland JS, Alex CP, Pauly TH, et al. A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics 1999;104:91-9.
11. Stark AR, Carlo WA, Tyson JE, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001;344:95-101.
12. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004;114:1649-57.
13. Gordon PV, Price WA, Stiles AD. Dexamethasone administration to newborn mice alters mucosal and muscular morphology in the ileum and modulates IGF-I localization. Pediatr Res 2001;49: 93-100.
14. Gordon PV, Price WA, Stiles AD, et al. Early postnatal dexamethasone diminishes transforming growth factor alpha localization within the ileal muscularis propria of newborn mice and extremely low-birth-weight infants. Pediatr Dev Pathol 2001;4:532-7.
15. Gordon PV, Moats-Staats BM, Stiles AD, et al. Dexamethasone changes the composition of insulin-like growth factor binding proteins in the newborn mouse ileum. J Pediatr Gastroenterol Nutr 2002;35:532-8.
16. Gordon PV, Paxton JB, Herman AC, et al. IGF-I accelerates ileal epithelial cell migration in culture and newborn mice and may be a mediator of steroid-induced maturation. Pediatr Res 2004;55:34-41.
17. Herman AC, Carlisle EM, Paxton JB, et al. Insulin-like growth factor-I governs submucosal growth and thickness in the newborn mouse ileum. Pediatr Res 2004;55:507-13.
18. Clapper ML, Coudry J, Chang WC. Beta-catenin-mediated signaling: a molecular target for early chemopreventive intervention. Mutat Res 2004;555:97-105.
19. Gasparini L, Ongini E, Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J Neurochem 2004;91:521-36.
20. Jimenez D, Martin MJ, Pozo D, et al. Mechanisms involved in protection afforded by L-arginine in ibuprofen-induced gastric damage: role of nitric oxide and prostaglandins. Dig Dis Sci 2002;47:44-53.
21. Chang JK, Wang GJ, Tsai ST, et al. Nonsteroidal anti-inflammatory drug effects on osteoblastic cell cycle, cytotoxicity, and cell death. Connect Tissue Res 2005;46:200-10.
22. Golde S, Coles A, Lindquist JA, et al. Decreased iNOS synthesis mediates dexamethasone-induced protection of neurons from inflammatory injury in vitro. Eur J Neurosci 2003;18:2527-37.
23. Matsumura M, Kakishita H, Suzuki M, et al. Dexamethasone suppresses iNOS gene expression by inhibiting NF-kappaB in vascular smooth muscle cells. Life Sci 2001;69:1067-77.
24. Kim YM, Lee JY, Choi SH, et al. RU486 blocks fasting-induced decrease of neuronal nitric oxide synthase in the rat paraventricular nucleus. Brain Res 2004;1018:221-6.
25. Jahng JW, Lee JY, Yoo SB, et al. Refeeding-induced expression of neuronal nitric oxide synthase in the rat paraventricular nucleus. Brain Res 2005;1048:185-92.
26. Takahashi T. Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. J Gastroenterol 2003;38:421-30.
27. Gow AJ, Chen Q, Hess DT, et al. Basal and stimulated protein S-nitrosylation in multiple cell types and tissues. J Biol Chem 2002;277:9637-40.
28. Shesely EG, Maeda N, Kim HS, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1996;93:13176-81.
29. Sigthorsson G, Simpson RJ, Walley M, et al. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002;122:1913-23.
30. Gow AJ, Davis CW, Munson D, et al. Immunohistochemical detection of s-nitrosylated proteins. Methods Mol Biol 2004;279:167-72.
31. Gaston B, Reilly J, Drazen JM, et al. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci U S A 1993;90:10957-61.
32. Huang PL, Dawson TM, Bredt DS, et al. Targeted disruption of the neuronal nitric oxide synthase gene. Cell 1993;75:1273-86.
33. Al-Shabrawey M, El-Remessy A, Gu X, et al. Normal vascular development in mice deficient in endothelial NO synthase: possible role of neuronal NO synthase. Mol Vis 2003;9:549-58.
34. Miller AA, Hislop AA, Vallance PJ, et al. Deletion of the eNOS gene has a greater impact on the pulmonary circulation of male than female mice. Am J Physiol Lung Cell Mol Physiol 2005;289:L299-306.
35. Torrents D, Prats N, Vergara P. Inducible nitric oxide synthase inhibitors ameliorate hypermotility observed after T. spiralis infection in the rat. Dig Dis Sci 2003;48:1035-49.
36. Gordon PV, Aschner JL. the Preemie iNO Subcommittee on Behalf of the NICHD Neonatal Research NetworkCan inhaled nitric oxide (iNO) alter the natural history of spontaneous intestinal perforations (SIP) in the ELBW infant? A post hoc analysis of the NICHD Premie iNO Study. Pediatr Acad Soc 2006;383:5570.
37. Van Meurs KP, Wright LL, Ehrenkranz RA, et al. Preemie Inhaled Nitric Oxide Study. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 2005;353:13-22.
38. Schreiber MD, Gin-Mestan K, Marks JD, et al. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003;349:2099-107.
39. Kinsella JP, Cutter GR, Walsh WF, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 2006;355:354-64.
40. Ballard RA, Truog WE, Cnaan A, et al., NO CLD Study Group-Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006;355:343-53.
41. Doctor A, Platt R, Sheram ML, et al. Hemoglobin conformation couples erythrocyte S-nitrosothiol content to O2 gradients. Proc Natl Acad Sci U S A 2005;102:5709-14.
42. Lancaster JR Jr, Gaston B. NO nitrosothiols: spatial confinement and free diffusion. Am J Physiol Lung Cell Mol Physiol 2004;287:L465-6.
43. Zaman K, Palmer LA, Doctor A, et al. Concentration-dependent effects of endogenous S-nitrosoglutathione on gene regulation by specificity proteins Sp3 and Sp1. Biochem J 2004;380:67-74.